Skip to content

Percutaneous High Frequency Alternating Current Stimulation in Healthy Volunteers With 30kHz

Percutaneous High Frequency Alternating Current Stimulation: Effects on Somatosensory and Motor Threshold in Healthy Volunteers With 30 kHz

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04884932
Enrollment
48
Registered
2021-05-13
Start date
2021-05-13
Completion date
2021-08-16
Last updated
2021-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Electrical Stimulation, Neuromodulation

Keywords

High-frequency alternating current, nerve block, somatosensory threshold, motor threshold, percutaneous electrical stimulation

Brief summary

High-frequency alternating currents of greater than 1 kHz applied on peripheral nerves has been used in animal studies to produce a motor nerve block. It has been evidenced that frequencies higher than 5 kHz are necessary to produce a complete peripheral nerve block in primates, whose nerve thickness is more similar to humans.

Detailed description

The previous studies with transcutaneous and percutaneous HFAC, suggest high-frequency stimulation (10 and 20 kHz) have an inhibitory effect over muscle strength and somatosensory threshold. However, the 30 kHz frequency has never been applied, and the hypothesis is that it can produce a greater blockage at the sensitive level and be a more comfortable application for the patient. The purpose of the present work is to determine if a greater blockage of the sensory component of the nerve occurs with this frequency and is to reduce the amount of current intensity needed using a percutaneous approach by apply two acupuncture needles near the nerve as electrodes.

Interventions

DEVICE30 kHz stimulation (Myomed 932, Enraf-Nonius)

A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 30 kHz. The stimulation intensity will be defined as that sufficient to produce a strong but comfortable sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft,Netherlands)

Sham stimulation will be delivered at a frequency of 30 kHz only during the first 30 seconds.

Sponsors

University of Castilla-La Mancha
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy volunteers * Ability to perform all clinical tests and understand the study process, as well as obtaining informed consent. * Tolerance to the application of electrotherapy. * That they have not diagnosed any pathology. * They do not present a contraindication to puncture and / or the application of electric currents.

Exclusion criteria

* Neuromuscular disease. * Epilepsy. * Trauma, surgery or pain affecting the upper limb * Osteosynthesis material in the upper limb. * Diabetes. * Cancer. * Cardiovascular disease. * Pacemaker or other implanted electrical device. * Take any drug (NSAIDs, corticosteroids, antidepressants, analgesics, antiepileptics, ...) during the study and in the previous 7 days. * Presence of tattoos or other external agent introduced into the treatment or assessment area. * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Amplitude Antidromic median sensory nerve action potentialImmediately after treatment at 20 minutesThe recording electrodes were placed on the second finger and the stimulus will be applied on the median nerve (above the elbow joint). The stimulus will consist of a train of 10 pulses (100 μs width), applied at supramaximal stimulation, presented at 1 Hz (DS7A, Digitimer Ltd). Peak-to-peak amplitude (PPA) will be registered with a specific software (Signal software, CED) and will be expressed in millivolts.
Amplitude of Antidromic median sensory nerve action potentialBaseline at 0 minutesThe recording electrodes were placed on the second finger and the stimulus will be applied on the median nerve (above the elbow joint). The stimulus will consist of a train of 10 pulses (100 μs width), applied at supramaximal stimulation, presented at 1 Hz (DS7A, Digitimer Ltd). Peak-to-peak amplitude (PPA) will be registered with a specific software (Signal software, CED) and will be expressed in millivolts.
Tactile ThresholdBaseline at 0 minutesThe tactile threshold will be measured with Von Frey filaments and will be expressed in millinewton
Pressure Pain ThresholdBaseline at 0 minutesThe PPT will be measured with an algometer and will be expressed in Newtons
Muscle strengthBaseline at 0 minutesMuscle strength will be measured with a dynamometer and will be expressed in Kgs.
Latency Antidromic median sensory nerve action potentialImmediately after treatment at 20 minutesThe recording electrodes were placed on the second finger and the stimulus will be applied on the median nerve (above the elbow joint). The stimulus will consist of a train of 10 pulses (100 μs width), applied at supramaximal stimulation, presented at 1 Hz (DS7A, Digitimer Ltd). Latency (NPL) will be registered with a specific software (Signal software, CED) and will be expressed in millisecond.
Latency of Antidromic median sensory nerve action potentialBaseline at 0 minutesThe recording electrodes were placed on the second finger and the stimulus will be applied on the median nerve (above the elbow joint). The stimulus will consist of a train of 10 pulses (100 μs width), applied at supramaximal stimulation, presented at 1 Hz (DS7A, Digitimer Ltd). Latency will be registered with a specific software (Signal software, CED) and will be expressed in millisecond.

Secondary

MeasureTime frameDescription
Numerical Discomfort Rate ScoreAfter the intervention at 35 minutesthe possible discomfort caused by the interventions will be assess by a numerical rate score. The NRS consists of a scale from 0 (no discomfort) to 10 (worst possible discomfort)
Numerical Pain Rate ScoreAfter the intervention at 35 minutesThe NRS consists of a scale from 0 (no pain) to 10 (worst possible pain)
Number of participants with intervention-related adverse effectsAfter the intervention at 35 minutesThe possible adverse effects caused by the interventions will be assess by a closed questionnaire, where the presence of any adverse effect would be qualified as 1 point and the negative presence of adverse effect as 0 point.
Blinding successAfter the intervention at 35 minutesBlinding of subjects and researchers will be assessed using the Bang questionary. It will be the question after the intervention, What type of treatment do you think you have received? Will be asked, with 5 items: (1) I firmly believe that I have received an experimental treatment; (2) I slightly believe that I have received an experimental treatment; (3) I strongly believe that I have received a placebo; (4) I slightly think I have received a placebo; (5) Don't know, don't answer., Index where -1 is blinded and 1 is unblinded.
Baseline nerve temperatureBaseline at 0 minutes, at 15 minutes, immediately after treatment at 20 minutes, and immediately after treatment at 30 minutesNerve temperature will be measured using a termodoppler (Celsius degrees)

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026